



News Updates: January 29, 2014

Compulsory License/Patents

Publication: The Financial Times

Edition: Online

Date: January 28, 2014

Headline: [Medical advances at risk from attacks on patent system](#)

Synopsis: Drug patents have been called into question in India where activists are demanding lower prices for drugs. Advances in medical science risk being slowed by attacks on the global patent system, UK experts have warned, amid growing scrutiny of intellectual property rights in the drugs industry. Researchers said incentives for private sector investment must be protected if further rapid progress was to be made towards tackling global health challenges.

Publication: The Times of India

Edition: Online

Date: January 28, 2014

Journalist: Rema Nagarajan

Headline: [Access to medicines issue splits the world, developing vs developed](#)

Synopsis: The recently concluded meeting of the World Health Organisation's executive board saw a sharp divide between developing and developed countries on the issue of South Africa's reforms of its intellectual property laws to enable affordable access to medicines. While several developing countries including India and Brazil came together to express support for the reforms, not a single delegate from the developed world expressed a word of solidarity for South Africa on the issue.

Drug regulation/FDA

Publication: Business Standard

Edition: Online

Date: 29 Jan 2014

Headline: [Ranbaxy execs scurry to regulator](#)

Synopsis: A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt. The executives spent about an hour there, explaining measures taken by the company to address issues raised by international regulators. Ranbaxy has been issued a warning that further failure to comply with norms might result in a ban in the domestic market.

Publication: The Hindu Business Line

Edition: Online

Date: 28 Jan 2014

Headline: [Ranbaxy promises action against employees responsible for US ban](#)

Synopsis: Ranbaxy Laboratories Ltd has said it will take "stern action" against the employees responsible for a recent import ban by the US drugs regulator on its Toansa plant in Punjab. A company official told Business Line the management is still analysing the situation and considering the actions need to be taken.

Publication: The Economic Times

Edition: Online

Date: 29 Jan 2014

Headline: [Ranbaxy plant at Toansa under UK and Aussie regulators' inspection](#)

Synopsis: Sanofi India is a subsidiary of Sanofi, one of the world's leading pharmaceutical companies. However, unlike other multinational pharmaceutical companies, Sanofi India was not analysts' favourite for quite some time. Its profitability has declined significantly over the last six years. Its EBITDA margin fell from around 25% in 2006 to around 16% in 2012. Its return on equity (RoE) also contracted from around 29% to 15% during the same period.

Publication: The Hindu Business Line

Edition: National

Date: January 28, 2014

Headline: [Govt mulls USFDA-like checks to keep MNC drug makers on toes](#)

Synopsis: Concerned by increasing regulatory action against domestic drug makers in the United States and Europe, the government is planning to initiate a similar system of checks on pharma manufacturers, including multi-national firms operating out of India.

The Drug Controller General of India is set to start a system of sudden inspections of manufacturing facilities of pharma companies, including those of multi-national companies and will take stringent action against any violations.